Category

AUTOINMMUNE DISEASES

Home > Therapeutic Areas > AUTOINMMUNE DISEASES (Page 9)

Buti M, Casado MA, Fosbrook L, Esteban R

 

 

 

Budget impact analysis of two different methods of evaluating EVR to peginterferon alfa-2b (PegIntron?) plus ribavirin (Rebetol) in genotype 1 naïve patients with chronic hepatitis C
55th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Boston, Massachusetts, EEUU. 29 oct-2 nov 2004

ACRMaymó J, Pérez C, Poveda JL, Casado MA, Fosbrook L, Merino P

 

 

Cost-analysis of infliximab and etanercept in the treatment of rheumatoid artritis patients in Spain, based on a Pharmacoeconomic model, and budgetary impact analysis of the results
Annual Scientific Meeting of American College of Rheumatology (ACR). San Antonio, Texas. 16-21 oct 2004

Wong JB, Ballina J, Fernández-Sueiro JL, García-Vadillo JA, González-Fernández C, González-Crespo MR, Gratacós J, Ivorra J, Navarro F, Tornero J, Casado MA, Fosbrook L, Pocovi A

 

Cost-effectiveness of infliximab for rheumatoid arthritis in Spain
4th Annual Congress of Rheumatology of the European League Against Rheumatism (EULAR). Berlin, Germany. 9-12 jun 2004

Wong JB, Ballina J, Fernández-Sueiro JL, García-Vadillo JA, González-Fernández C, González-Crespo MR, Gratacós J, Ivorra J, Navarro F, Tornero J, Casado MA, Fosbrook L, Pocovi A

 

Coste-efectividad de infliximab en pacientes con artritis reumatoide en España
XXX Congreso Nacional de la Sociedad Española de Reumatología (SER). Barcelona, España. 19-21 may 2004

Maymó J, Pérez C, Poveda JL, Fosbrook L, Casado MA, Pocoví A, Merino P

 

 

Análisis de costes de infliximab y etanercept en el tratamiento de pacientes con artritis reumatoide en España basado en un modelo farmacoeconómicos
Rev Esp Reumatol. 2004;31:425-33